ITBMed in brief

ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for organ transplantation, stem cell transplantation, and gene therapy. The lead candidate drug Siplizumab is a monoclonal antibody in late-stage clinical development, which has shown significant potential in transforming the life for organ transplant patients, by allowing the complete discontinuation of all immunosuppression treatment and restoration of a normal life.

ITBMed also has a strong preclinical research and development profile, in collaboration with Columbia University, New York, USA, that has the potential to provide novel IP and break ground for new indications and treatments.

Key facts

  • Revolutionizing therapy for organ transplant patients, allowing complete immunosuppression withdrawal
  • Siplizumab – candidate monoclonal antibody drug with completed Phase I/II trials in kidney transplantation
  • Clinical trials demonstrate improved efficacy, improved safety and increased quality of life, as well as potential health care cost savings when using Siplizumab-based regimen in organ transplantation
  • Treatment potential in several areas such as organ transplantation, stem cell transplantation, and gene therapy
  • World-leading medical and scientific advisors
  • Board of Directors with long pharma, biotech, and medical expertise
  • Based in Stockholm, Sweden and New York, USA